Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Rafael Fonseca MD

Rafael Fonseca MD

Chief Innovation Officer, Mayo Clinic; Getz Family Professor of Cancer, Professor of Medicine, Mayo Clinic School of Medicine, Phoenix, Arizona

Dr. Rafael Fonseca is the Getz Family Professor of Cancer, Professor of Medicine, Chief Innovation Officer, and a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona. He is a member of the Mayo Clinic Board of Governors and Board of Trustees.

Dr. Fonseca's practice has focused on the diagnosis and treatment of plasma cell disorders and leading the multiple myeloma team in its efforts to develop a better understanding of the disease and its impact on patients.

Throughout his training and career, Dr. Fonseca has received numerous awards and honors. Most notably, he is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. Dr. Fonseca holds memberships and serves in positions for organizations such as the American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, and the International Myeloma Society.

Dr. Fonseca serves as reviewer and in editorial capacities for medical publications including Blood, The Lancet, Nature Medicine, Cancer Cell, Leukemia, and The New England Journal of Medicine, among others. He has given many national and international presentations as a visiting professor, and has authored numerous articles (over 300), book chapters, editorials, abstracts, and letters.

Disclosures

  • Consultant: AbbVie; Adaptive Biotechnologies; AMGEN; AstraZeneca; Bayer; Binding Site; BMS (Celgene); Millennium Takeda; Jansen; Juno;, Kite; Merck; Pfizer; Pharmacyclics; Regeneron; Sanofi.
  • Advisory Board: Adaptive Biotechnologies; Caris Life Sciences; ONCOtracker
  • Board of Directors: Antengene (for profit); AZBio (not for profit)
  • Patent for FISH in MM (~$2000/yr)

Recent Contributions to PracticeUpdate:

  1. Minimal Residual Disease and Survival Outcomes in Patients With Multiple Myeloma After ASCT and Maintenance With Lenalidomide
  2. Long-Term Follow-Up of Combination of Anti–B-Cell Maturation Antigen and Anti–CD19 CAR T Cells in Multiple Myeloma
  3. Blinatumomab Maintenance After Allogeneic HCT for B-ALL
  4. Isatuximab + Pomalidomide + Dexamethasone vs Pomalidomide + Dexamethasone for Relapsed and Refractory Multiple Myeloma
  5. Attrition Rate and Economic Burden of Multiple Myeloma Progression
  6. Real-World Analysis in Treatment Approaches for Multiple Myeloma
  7. Clinical Recommendations for Relapsed and Refractory Multiple Myeloma
  8. Treatment of Relapsed and Refractory Multiple Myeloma
  9. ASH 2021: Findings From Myeloma Studies
  10. First-Line Daratumumab, Lenalidomide, and Dexamethasone for Transplant-Ineligible Patients

Elsewhere

Most Read This Week

Recently Updated